From:
`Sent:
`To:
`
`Cc:
`Subject:
`
`Emer Simic <esimic@greengriffith.com>
`Tuesday, April 26, 2016 3:19 PM
`Burgy, Aziz; Matt Phillips; Robert Green; 'Lauren Stevens'; 'Dennis Bennett'; Jessica
`Tyrus
`Silverstein, David H.
`RE: IPR-2015-01117 and 01127
`
`Aziz: 
` 
`Horizon will not oppose Par’s proposed motion to file its objections but reserves the right to oppose any Par motion to 
`exclude on grounds that Par’s objections were not timely filed or are otherwise deficient. 
` 
`Regards, 
` 
`Emer. 
` 
`Emer L. Simic 
`Member 
`
`  
`Green, Griffith & Borg‐Breen LLP 
`esimic@greengriffith.com 
`Main: 312.883.8000  |  Direct: 312.883.8017 
`NBC Tower, 455 North Cityfront Plaza Drive, Suite 3100 
`Chicago, Illinois 60611 
`greengriffith.com 
` 
`This email transmission is confidential and intended solely for the person or organization to whom it is 
`addressed. It may contain privileged and confidential information. If you are not the intended recipient, you 
`must not copy, distribute or take any action in reliance on the information contained in this email. If you have 
`received this email in error, please notify the sender as soon as possible and delete the email and any 
`attachments from your system. Thank you. 
`
`   
`
`From: Burgy, Aziz [mailto:aburgy@axinn.com]  
`Sent: Monday, April 25, 2016 9:33 PM 
`To: Matt Phillips <matthew.phillips@renaissanceiplaw.com>; Emer Simic <esimic@greengriffith.com>; Robert Green 
`<rgreen@greengriffith.com>; 'Lauren Stevens' <LStevens@horizonpharma.com>; 'Dennis Bennett' 
`<dennisbennett@globalpatentgroup.com>; Jessica Tyrus <jtyrus@greengriffith.com> 
`Cc: Silverstein, David H. <DSilverstein@axinn.com> 
`Subject: RE: IPR‐2015‐01117 and 01127 
` 
`Dear Counsel,
`
` I
`
` write in regard to Par’s objections to the evidence cited in each of Horizon’s March 28, 2016 Responses. Par
`timely served its objections on Horizon on April 4, 2016, but inadvertently failed to concurrently file its
`
`1
`
`Par Pharmaceutical, Inc. Ex. 1036
`Par v. Hyperion, IPR2015-01117, IPR2015-01127
`Page 1 of 3
`
`

`
`objections on the relevant dockets. Par plans to file a motion to file its previously served objections. Please let
`us know if Horizon consents to this motion.
`
`Thanks,
`
`Aziz
`Aziz Burgy
`Partner 
`  
`
` 
`
`  
`
`Axinn, Veltrop & Harkrider LLP 
`950 F Street, NW 
`Washington, DC 20004 
`Office 202.721.5417 
`aburgy@axinn.com 
`Axinn.com
`
`Click here to send a secure file via Sharefile
`
`From: Matt Phillips [mailto:matthew.phillips@renaissanceiplaw.com]
`Sent: Friday, March 25, 2016 5:21 PM
`To: Burgy, Aziz; 'Emer Simic'; 'Robert Green'; 'Lauren Stevens'; 'Dennis Bennett'; 'Jessica Tyrus'
`Cc: Silverstein, David H.; Matt Phillips
`Subject: RE: IPR-2015-01117 and 01127
` 
`Aziz, 
` 
`The errata appears to be fine.  I suggest that we attach it to the transcript exhibit we file with our responses on 
`Monday.  Please let me know if you object to that.  Thanks. 
` 
`‐‐Matt 
` 
`Matthew C. Phillips, Partner 
`Renaissance IP Law Group LLP 
`7327 SW Barnes Road #521, Portland, Oregon 97225 
`MAIN: 503‐419‐6425 * FAX: 503‐517‐9199 * DIRECT: 503‐964‐1129 
`matthew.phillips@renaissanceiplaw.com 
`
`   
`
`  
`
`From: Burgy, Aziz [mailto:aburgy@axinn.com]
`Sent: Friday, March 25, 2016 11:27 AM
`To: Emer Simic; Robert Green; Matt Phillips; 'Lauren Stevens'; Dennis Bennett; Jessica Tyrus
`Cc: Silverstein, David H.
`Subject: IPR-2015-01117 and 01127
` 
`Dear Counsel, 
` 
`Please let us know if Patent Owner consents to Petitioner filing the attached errata for the deposition of N. Sondheimer.
`
`Thanks, 
` 
`
`2
`
`Par Pharmaceutical, Inc. Ex. 1036
`Par v. Hyperion, IPR2015-01117, IPR2015-01127
`Page 2 of 3
`
`

`
`Aziz 
` 
`Aziz Burgy
`Partner 
`  
`
` 
`
`  
`
`Axinn, Veltrop & Harkrider LLP 
`950 F Street, NW 
`Washington, DC 20004 
`Office 202.721.5417 
`aburgy@axinn.com 
`Axinn.com
`
`Click here to send a secure file via Sharefile
` 
`
`**********************************************************************
`
`Notice: The information contained in this electronic mail and any attached documents from Axinn, Veltrop &
`Harkrider LLP is confidential. This email may be an attorney-client communication, and as such is privileged
`and confidential. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use
`of the content of this information is prohibited. If you have received this electronic mail in error, please notify
`us immediately by telephone (212) 728-2200/(860) 275-8100 or by reply electronic mail to the sender.
`
`IRS Circular 230 disclosure: To ensure compliance with requirements imposed by the IRS, we inform you that
`any U.S. federal tax advice contained in this communication (including any attachments) is not intended or
`written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue
`Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.
`
`**********************************************************************
`
`**********************************************************************
`
`Notice: The information contained in this electronic mail and any attached documents from Axinn, Veltrop &
`Harkrider LLP is confidential. This email may be an attorney-client communication, and as such is privileged
`and confidential. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use
`of the content of this information is prohibited. If you have received this electronic mail in error, please notify
`us immediately by telephone (212) 728-2200/(860) 275-8100 or by reply electronic mail to the sender.
`
`IRS Circular 230 disclosure: To ensure compliance with requirements imposed by the IRS, we inform you that
`any U.S. federal tax advice contained in this communication (including any attachments) is not intended or
`written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue
`Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.
`
`**********************************************************************
`
`3
`
`Par Pharmaceutical, Inc. Ex. 1036
`Par v. Hyperion, IPR2015-01117, IPR2015-01127
`Page 3 of 3